Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Jennifer Wright Oliver"'
Autor:
Toni K. Choueiri, Bradley Alexander McGregor, Neil J. Shah, Aung Bajaj, Jad Chahoud, Bert O'Neil, Joel Michalski, Benjamin Garmezy, Lixian Jin, Jennifer Wright Oliver, Yijia Wang, Darren Tayama, Robert J. Motzer
Publikováno v:
Journal of Clinical Oncology. 40:TPS4600-TPS4600
TPS4600 Background: XL092 is a novel oral inhibitor of receptor tyrosine kinases, including MET, VEGFR2, and TAM kinases (AXL, MER), which are implicated in tumor growth, metastasis, angiogenesis, and immune suppression of the tumor microenvironment.
Autor:
Jaume Capdevila, Bruce Robinson, Steven I. Sherman, Barbara Jarząb, Chia-Chi Lin, Fernanda Vaisman, Ana Hoff, Erika Hitre, Daniel W. Bowles, Denise Williamson, Jennifer Wright Oliver, Bhumsuk Keam, Marcia S. Brose
Publikováno v:
Journal of Clinical Oncology. 40:6081-6081
6081 Background: DTC comprises multiple histology subtypes, the most common being papillary and follicular. Based on results of the phase 3 COSMIC-311 trial, the multikinase inhibitor cabozantinib was recently approved by FDA for the treatment of pts
Autor:
Kate Lorig, Jennifer Wright Oliver, Christina K. Slee, Richard L. Kravitz, Peter Franks, Tim Grennan, Donna Kalauokalani, Richard L. Street, Daniel J. Tancredi, Theodore Wun
Publikováno v:
Pain. 152:1572-1582
We aimed to determine the effectiveness of a lay-administered tailored education and coaching (TEC) intervention (aimed at reducing pain misconceptions and enhancing self-efficacy for communicating with physicians) on cancer pain severity, pain-relat
Autor:
David S. Ettinger, Lawrence Garbo, R. McNally, Paul Conkling, Arkadiusz Z. Dudek, Ravi Salgia, Chirag Shah, David R. Spigel, Carlos Alemany, Vicram Gupta, Markus F. Renschler, Jennifer Wright Oliver, Paul Lorigan, Robert M. Jotte
Publikováno v:
Journal of Clinical Oncology. 28:2598-2603
Purpose Amrubicin is a synthetic anthracycline with potent topoisomerase II inhibition. This phase II study was conducted to confirm safety and activity of amrubicin in the treatment of refractory small-cell lung cancer (SCLC). Patients and Methods P
Autor:
Pratik S. Multani, Rupal Patel, Marwan Fakih, Albert C. Lockhart, Manish R. Patel, Siqing Fu, Jennifer Wright Oliver, Alexander Drilon, Anthony J. Olszanski, Ding Wang, Lyudmila Bazhenova
Publikováno v:
Journal of Clinical Oncology. 34:2574-2574
2574Background: RXDX-105 is a multikinase inhibitor that has demonstrated potent inhibition of RET. RXDX-105 is also active against BRAF. RET alterations are associated with the development of various types of cancer. Acquired BRAF mutations can resu
Autor:
Paul Conkling, Matthew D. Galsky, Markus F. Renschler, Jennifer Wright Oliver, Leonard Klein, R. McNally, Craig W. Reynolds, James F. Fitzgibbons, Robert M. Jotte
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(3)
Purpose This phase II study evaluated the safety and efficacy of single-agent amrubicin versus topotecan in patients with small-cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy. Patients and Methods Patients were randomly a
Autor:
Frederick J. Meyers, Richard L. Kravitz, Peter Franks, Jennifer Wright Oliver, Donna Kalauokalani
Publikováno v:
Pain medicine (Malden, Mass.). 8(1)
Davis, California, USA ABSTRACT Purpose. Minority patients with cancer experience worse control of their pain than do their white counterparts. This disparity may, in part, reflect more miscommunication between minority patients and their physicians.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19(8)
PURPOSE: An estimated 42% of cancer patients suffer from poorly controlled pain, in part because of patient-related barriers to pain control. The objective of this study was to evaluate the effect of an individualized education and coaching intervent
Autor:
Paul Conkling, L. Klein, Jennifer Wright Oliver, C. Shah, M. Renschler, Robert M. Jotte, J.F. Fitzgibbons, Craig W. Reynolds, R. McNally, M. Galsky
Publikováno v:
European Journal of Cancer Supplements. 7:540-541
Autor:
David R. Spigel, Paul Conkling, Paul Lorigan, R. McNally, V. Gupta, David S. Ettinger, Lawrence Garbo, Markus F. Renschler, Jennifer Wright Oliver, Robert M. Jotte
Publikováno v:
ResearcherID
8103 Background: Amrubicin (AMR), a third-generation synthetic anthracycline and potent topoisomerase II inhibitor, is approved in Japan for the treatment of lung cancer. Patients (pts) with SCLC, who are refractory to first-line chemotherapy or prog